Results

1–10 of 44 results for Retinitis Pigmentosa

Peripheral Retinal Vessels in Retinitis Pigmentosa
Hossein Ameri, MD, PhD, FRCSI, MRCOphth
Annual Meeting Talks
2025
Extended Efficacy and Safety of MCO-010 Optogenetic Therapy for RP: 126-Week Results From the RESTORE Follow-Up Study (REMAIN)
David S Liao, MD, PhD
Annual Meeting Talks
2025
A Novel Modifier Gene Therapy for Retinitis Pigmentosa: 2-Year Results of a Phase 1/2, Multicenter, Dose-Escalation Study of Subretinal OCU400
Syed Shah, MD
Annual Meeting Talks
2025
Subretinal Laru-zova Gene Therapy for XLRP: 24-Month Results of the Randomized, Controlled, Multicenter Phase 2 SKYLINE Trial
Robert Andrew Sisk, MD, FACS, FASRS
Annual Meeting Talks
2025
Epidemiology of Inherited Retinal Diseases in the United States- IRIS Registry Intelligent Research In Sight Analysis
Ahmad Al-Moujahed, MD, PhD, MPH
Annual Meeting Talks
2023
Surgical Case Conference: Sengul Ozdek, MD, FEBO, FASRS
Sengul Ozdek, MD, FEBO, FASRS
Annual Meeting Talks
2024
One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Annual Meeting Talks
2024
BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)
Michael A. Singer, MD
Annual Meeting Talks
2024
Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase 2 Skyline Trial
Rajiv Anand, MD, FRCS, FASRS
Annual Meeting Talks
2024
Clinical Characterization of Hexokinase 1 (HK1) Mutations Causing Autosomal Dominant Pericentral Retinitis Pigmentosa
Patrick Staropoli, MD
Annual Meeting Talks
2024